ClinicalTrials.gg
RecruitingNCT04877288Updated Aug 31, 2026

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

A Phase 3 interventional study of Belatacept and Tacrolimus in Renal Allograft Recipients, sponsored by Bristol-Myers Squibb. Recruiting at 38 sites in 10 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin inhibitor-based regimen and their adherence to immunosuppressive medications.

02

Conditions studied

  • Renal Allograft Recipients

Keywords

  • Acute rejection
  • Belatacept
  • Calcineurin inhibitors (cyclosporine, tacrolimus)
  • Conversion
  • Donor-specific antibodies
  • eGFR
  • Immunosuppressive regimen
  • Adolescent kidney transplant recipients
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adolescents 12 to less than 18 years of age
  • Recipients of a renal allograft from a living or deceased donor transplanted at least 6 calendar months prior to enrollment
  • Receiving a stable regimen of a calcineurin inhibitor (CNI), with mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium/mycophenolate mofetil (EC-MPS/MPA), with or without daily for ≥ 30 days prior to randomization
  • Clinically stable renal function during the 12-week period prior to screening, in the opinion of the investigator and based on protocol-defined criteria for proteinuria and estimated (eGFR)
  • Serologic evidence of past exposure to Epstein-Barr virus (EBV) and current absence of EBV DNA replication at or prior to renal transplantation and during the Screening period
  • Completion of an initial course of SARS-CoV-2 vaccination per local standard of care, a minimum of 6 weeks prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Recipients with EBV serostatus negative or unknown at screening or at transplant
  • Treatment for -proven acute rejection (BPAR) of any degree of severity within 6 calendar months prior to enrollment
  • Biopsy-confirmed antibody-mediated acute rejection at any time with the current allograft
  • Banff 97 grade IIA or higher acute cellular rejection (or equivalent), or treatment with plasmapheresis or rituximab for any acute rejection at any time with the current allograft
  • Current evidence or past history of active or inadequately treated latent tuberculosis (TB) infection
  • Previously treated with belatacept or previously enrolled in a belatacept trial with their present allograft

Other inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap

    Conversion followed by tapering and discontinuation of the calcineurin inhibitor (CNI)

    Biological: Belatacept · Drug: Tacrolimus · Drug: Cyclosporine A · Drug: Mycophenolate Mofetil · Drug: Enteric Coated Mycophenolate Sodium · Drug: Corticosteroids

  • Active comparator
    Arm 2: Continue calcineurin inhibitor-based regimen

    Drug: Tacrolimus · Drug: Cyclosporine A · Drug: Mycophenolate Mofetil · Drug: Enteric Coated Mycophenolate Sodium · Drug: Corticosteroids

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants who survive with a functional graft with estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2 (updated Schwartz formula) at 24 months post-randomization

    Time frame: 24 months

Secondary outcomes

  1. Participant and graft survival: Proportion of participants who survive with a functioning graft

    Time frame: 6, 12 and 24 months

  2. Participant and graft survival: Proportion of participants who survive

    Time frame: 6, 12, and 24 months

  3. Participant and graft survival: Proportion of participants who experience death-censored graft loss

    Time frame: 6, 12, and 24 months

  4. Acute rejection: Incidence of clinically suspected biopsy-proven acute rejection (BPAR)

    Time frame: 3, 6, 12, and 24 months

  5. Acute rejection: Severity of clinically suspected, biopsy confirmed rejection as determined by locally and centrally reviewed histopathology

    Time frame: 3, 6, 12, and 24 months

  6. Renal function as assessed by: Serum creatinine concentration

    Time frame: Up to 24 months

  7. Renal function as assessed by: Estimated GFR (eGFR per updated Schwartz combined equation)

    Time frame: Up to 24 months

  8. Renal function as assessed by: eGFR per updated bedside Schwartz approximating equation

    Time frame: Up to 24 months

  9. Renal function as assessed by: eGFR per Full Age Spectrum (FAS) equation of Potell et al

    Time frame: Up to 24 months

  10. Renal function as assessed by: eGFR per age and sex-dependent equation of Pierce et al

    Time frame: Up to 24 Months

  11. Proteinuria, as assessed by urinary protein:creatinine ratio (UPCR), as determined from single-voided urine specimens

    Time frame: Up to 24 months

  12. Slope of change in eGFR over time, as assessed by baseline-adjusted mean eGFR determinations at protocol-specified study visits

    Time frame: Up to 24 months

  13. Adherence to immunosuppressive medications as assessed by variation in calcineurin inhibitor pre-dose whole blood concentrations by summaries over time of monitored adherence to orally administered immunosuppressive medications

    Time frame: up to 24 months

  14. Adherence to immunosuppressive medications, as assessed by: Variations in pre-dose concentrations of calcineurin inhibitor in whole blood

    Time frame: Up to 24 months

  15. Adherence to immunosuppressive medications, as assessed by: 7-day recall of missed and late doses of each orally administered immuno-suppressive medication at protocol-specified study visits

    Time frame: Up to 24 months

  16. Adherence to immunosuppressive medications, as assessed by: Monitoring of compliance with monthly belatacept infusions

    Time frame: Up to 24 months

  17. Adherence to immunosuppressive medications, as assessed by: Periodic review of parents' and patients' perceived barriers to adherence to the prescribed immunosuppressive medications regimen

    Time frame: Up to 24 months

  18. Mean blood pressure over time

    Time frame: Up to 24 months

  19. Mean blood pressure changes from baseline over time

    Time frame: Up to 24 months

  20. Intensity of antihypertensive drug therapy, defined as the total number of medications used to maintain BP control

    Time frame: Up to 24 months

  21. Monitoring of safety laboratory parameters over time: Mean fasting lipid profiles

    Time frame: Up to 24 months

  22. Monitoring of safety laboratory parameters over time: Fasting blood glucose concentrations

    Time frame: Up to 24 months

  23. Monitoring of safety laboratory parameters over time: Hemoglobin A1c concentrations

    Time frame: Up to 24 months

  24. Donor Specific antibodies (DSA): Proportion of participants with pre-existing anti-human leukocyte antigen (HLA) DSAs at baseline and with de novo anti-HLA DSA post-randomization

    Time frame: 6, 12, and 24 months

  25. Immunogenicity of belatacept as determined by the proportion of participants with detectable serum anti-belatacept antibodies

    Time frame: 6, 12, and 24 months

  26. Belatacept pre-dose (C0) serum concentrations

    Time frame: Up to 24 months

  27. Mean percent belatacept CD86 receptor occupancy

    Time frame: Baseline

  28. Post-randomization changes from baseline percent belatacept CD86 receptor occupancy

    Time frame: 6, 12, and 24 months

  29. Safety and tolerability of belatacept following conversion: Incidence of Adverse Events (AEs)

    Time frame: up to 24 months

  30. Safety and tolerability of belatacept following conversion: Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 24 months

  31. Safety and tolerability of belatacept following conversion: Incidence of laboratory marked abnormalities

    Time frame: Up to 24 months

  32. Proportion of participants within each stage of the Tanner staging scale

    The Tanner scale is a measure of pubertal development (sexual maturation) in children and adolescents with components described for each sex, rated separately on a scale of stage one to stage five, with 1 for preadolescent and 5 for mature/adult

    Time frame: Up to 24 months

  33. Linear growth (height)

    Time frame: Up to 24 months

07

Study locations

16 of 38 sites recruiting
  • Local Institution - 0042
    Birmingham, Alabama 35233, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0041
    Los Angeles, California 90095, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0014
    Washington D.C., District of Columbia 20010, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0022
    Hollywood, Florida 33021, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0045
    Miami, Florida 33136, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0049
    Atlanta, Georgia 30322, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0033
    Chicago, Illinois 60611, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0017
    Baltimore, Maryland 21287, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0044
    Boston, Massachusetts 02115, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0043
    St Louis, Missouri 63110, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0024
    Durham, North Carolina 27710, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0025
    Cincinnati, Ohio 45229, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0048
    Cleveland, Ohio 44124, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0052
    Portland, Oregon 97239, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0038
    Seattle, Washington 98105, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Italiano de Buenos Aires
    ABB, Buenos Aires F.D. C1199ABB, Argentina
    Recruiting
    • Paula Coccia, Site 0060 · Contact5491140727138
  • Instituto de Trasplantes y Alta Complejidad
    Buenos Aires, 1425, Argentina
    Recruiting
    • Laila Rodríguez Rilo, Site 0062 · Contact+5491139877200
  • UZ Gent-Paediatric Nephrology and Rheumatology Department
    Ghent, 9000, Belgium
    Recruiting
    • Agnieszka Prytula, Site 0047 · Contact+3293320368
  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
    Nantes, Loire-Atlantique 44093, France
    Recruiting
    • Gwenaelle Roussey, Site 0055 · Contact+33253482237
  • Bordeaux University Hospital - Pellegrin-Pediatrics
    Bordeaux, 33076, France
    Recruiting
    • Jerome Harambat, Site 0056 · Contact+33661986263
  • Hospices Civils de Lyon - Hôpital Femme Mère Enfant-néphrologie pédiatrique
    Bron, 69677, France
    Recruiting
    • Anne-Laure SELLIER-LECLERC, Site 0028 · Contact+33427856128
  • Hopital De La Timone
    Marseille, 13005, France
    Recruiting
    • Florentine Garaix, Site 0054 · Contact+334 91 38 83 83
  • Hopital Necker
    Paris, 75015, France
    Recruiting
    • Olivia Boyer, Site 0027 · Contact+33689031066
  • Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universita
    Paris, 75019, France
    Recruiting
    • Julien Hogan, Site 0029 · Contact33638691391
  • Universitaetsklinikum Essen
    Essen, North Rhine-Westphalia 45122, Germany
    Recruiting
    • Lars Pape, Site 0057 · Contact+495115323283
  • Universitaetsklinikum Koeln-Klinik und Poliklinik für Kinder- und Jugendmedizin, Abteilung für Pädia
    Cologne, 50937, Germany
    Recruiting
    • Lutz Weber, Site 0010 · Contact0049-173-5842620
  • Local Institution - 0011
    Hamburg, 20246, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0026
    Heidelberg, 69120, Germany
    Recruiting
    • Site 0026 · Contact
  • IRCCS Istituto Giannina Gaslini
    Genoa, Liguria 16147, Italy
    Recruiting
    • ENRICO VERRINA, Site 0059 · Contact003901056362630
  • Local Institution - 0030
    Milan, 20122, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ospedale Regina Margherita-S.C Nefrologia, Dialisi e Trapianto Renale
    Torino, 10126, Italy
    Recruiting
    • Licia Peruzzi, Site 0036 · Contact0039 0113135365
  • Emma Children (AMC)
    Amsterdam, 1105 AZ, Netherlands
    Recruiting
    • Antonia Bouts, Site 0015 · Contact0031610061279
  • Local Institution - 0061
    Oslo, N-0027, Norway
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0001
    Barcelona, 08035, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0012
    Rivas-Vaciamadrid, 28523, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0003
    Seville, 41013, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0008
    Manchester, M13 9WL, United Kingdom
    Completed

    Not enrolling at this site — choose another above.

  • Queen's Medical Centre, Nottingham University Hospitals-Children's Clinical Research Team
    Nottingham, NG7 2UH, United Kingdom
    Recruiting
    • Jon Jin Kim, Site 0009 · Contact01159249924
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for Dec 2032, 137 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2021
First posted
May 7, 2021
StartActual
Jul 21, 2021
Primary completionEst.
Dec 30, 2032
CompletionEst.
Jun 30, 2034
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04877288
Responsible party
Sponsor
First posted
May 7, 2021
Start date
Jul 21, 2021
Primary completion
Dec 30, 2032 (estimated)
Completion
Jun 30, 2034 (estimated)
Last update
Aug 31, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion